These A portion of our assays were developed and funded by the Small Business Innovation Research program (SBIR) of the National Cancer Institute under Contract Number HHSN261200700037C, in collaboration with NCI’s Clinical Proteomic Technologies for Cancer Initiative’s Antibody Characterization Program, Contract Number HHSN261200800045C, and the Cancer Prevention and Research Institute of Texas (CPRIT).
The following antibodies, used in the OncologyMAP® v. 2.0, were originally supplied by the National Cancer Institute’s Antibody Characterization Program, a component of the Clinical Proteomic Technologies for Cancer initiative in the Office of Cancer Clinical Proteomics Research.
|Antibody||Clinical Proteomic Technologies for Cancer Identifier|
|Nucleoside diphosphate kinase B||CPTC-NME2-1|
|Nucleoside diphosphate kinase B||CPTC-NME2-2|